Home > Browse Issues > Vol.37 No.12

Effects of PRMT5 on Cell Proliferation and Apoptosis in Hepatocellar Carcinoma Cells


Zhang Youli1, Ge Lu1, Lu Ying1, Hu Changlong1, Zhang Xingxing1, Peng Wanxin2, He Junbo1, Gong Aihua2,3, Xu Min1*
1Affiliated Hospital of Jiangsu University, Zhenjiang 212000, China; 2State Key Laboratory of Oncogenes and Related Genes, Zhenjiang 212000, China; 3School of Medicine, Jiangsu University, Zhenjiang 212000, China
Abstract: The paper aimed at investigating the effects of PRMT5 on cell proliferation and apoptosis in hepatocellular carcinoma cells. PRMT5 short hairpin RNA (shRNA) sequence was designed and inserted into pLKO.1-TRC vector, then packaging lentivirus to infect SMMC-7721 and BEL-7402 cells. Stable infected cells were obtained by puromycin screening. shRNA silencing efficiency was tested by Western blot and qPCR. Cell proliferation activity was detected by CCK-8. Colony formation ability was detected by plate colony assay. Apoptosis was observed by flow cytometry. The expressions of cell proliferation- and apoptosis-related protein were detected by Western blot. The specific shRNA against PRMT5 plasmid (sh-PRMT5) was successfully constructed and infected into SMMC-7721 and BEL-7402 cells. The results of Western blot and qPCR demonstrated that the expression of PRMT5 was efficiently inhibited at both protein and mRNA levels (P<0.05). It revealed that PRMT5 depletion decreased cell proliferation (P<0.05). It was found that knockdown of PRMT5 reduced the protein levels of cyclin B1, cyclin D1, cdc20 and cdc25B, respectively (P<0.05). It showed that knockdown of PRMT5 inhibited cell colony formation ability. It was found that knockdown of PRMT5 induced the apoptosis (P<0.05). It indicated that knockdown of PRMT5 activated Caspase-3 and reduced the ratio of Bcl-2 to Bax in protein levels (P<0.05). Taken together, downregulation of PRMT5 inhibited cell proliferation and induced the apoptosis of hepatocellar carcinoma cells. It may provide a new therapeutic target for the clinical treatment of hepatocellular carcinoma


CSTR: 32200.14.cjcb.2015.12.0006